E. David Crawford, MD, Editor-in-Chief

LEARNING CENTERS

Next Generation Androgen Deprivation Therapy

Editor: Celestia S. Higano, MD

Next Generation Genomics and Biomarkers

Editor: Leonard G. Gomella, MD

Next Generation Imaging

Editor: Gerald L. Andriole, MD

Next Generation nmCRPC

Editor: Jonathan Henderson, MD

Next Generation Nocturia

Editor: Kevin T. McVary, MD

LATEST CONTENT

PCa Commentary | Volume 141 – December 2019

PCa Commentary | Volume 141 – December 2019

  PCa Commentary | Volume 141 - December 2019 Posted by Edward Weber | December 2019 PARP INHIBITION THERAPY — Clinical importance of genetic variants of BRCA 1/2 and ATM in men with metastatic castration-resistant prostate cancer.  Something big is emerging in...

PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM Mutations

PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM Mutations

Maha H. Hussain, MD, FACP, FASCO, and Celestia S. Higano, MD, discuss the PROfound Trial, which demonstrated increased radiographic progression-free survival (rPFS) with the use of olaparib for mCRPC patients displaying the genetic mutations BRCA1, BRCA2, and ATM. Dr. Hussain outlines previous research of genetic mutations in mCRPC that led to this study, the study design and rationale of using two cohorts with specific mutations (BRCA1, BRCA2, and ATM) and non-specific mutations (other genetic alterations), and results that demonstrate promise for gene-targeted therapies in the future.

Multi-Parametric MRI

Multi-Parametric MRI

Masoom Haider, MD, provides an overview of the current state of multiparametric MRI, especially in the setting of biopsy-naive patients with elevated PSA levels. He then describes an MRI-directed biopsy pathway and how to integrate it into prostate cancer care.

Upper Tract Urothelial Cancer: Challenges and Opportunities for Treating the Unmet Medical Need

Upper Tract Urothelial Cancer: Challenges and Opportunities for Treating the Unmet Medical Need

David S. Morris, MD, FACS, discusses current methods of diagnosing and risk-stratifying upper tract urothelial cancer (UTUC), as well as the implications of disease risk on treatment decisions. He notes the unmet need for an effective kidney-sparing option for low-risk patients, and the potential for chemoablation with UGN-101 to address this need based on findings from the OLYMPUS trial.

RADAR III: Next Generation Imaging

RADAR III: Next Generation Imaging

E. David Crawford, MD, reviews the findings and recommendations from the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) III working group, and how its prior iterations, RADAR I and II, provided the rationale for the RADAR III manuscript. He discusses the next generation imaging modalities and radiotracers covered in RADAR III, as well as the group’s consensus on how they should be implemented in the evaluation of patients with prostate cancer.

Latest Features

PT0 after NAC: Implications for Bladder Sparing and Prognosis

Androgen Receptor Targeted Treatments of Prostate Cancer Slide Deck

Pivotal Trial of MRI-Guided Transurethral Ultrasound Ablation in Men with Localized Prostate Cancer

Join the GRU Community

– Why Join? –